Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
Avan J Armaghani, Hyo Sook Han Department of Breast Oncology, Moffitt McKinley Outpatient Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USACorrespondence: Avan J Armaghani Email avan.armaghani@moffitt.orgAbstract: Hormone receptor positive, human epidermal growth fact...
Guardado en:
Autores principales: | Armaghani AJ, Han HS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f0721596dfc64a26b674b5e4d84fb1a4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
por: Natalya V. Mazurina, et al.
Publicado: (2021) -
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
por: Irina V. Poddubnaya, et al.
Publicado: (2021) -
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
por: Tatiana N. Sokolova, et al.
Publicado: (2021) -
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
por: Editorial Board
Publicado: (2021) -
Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
por: Chang DY, et al.
Publicado: (2021)